Photo of Akira Kato, Ph.D.

Akira Kato, Ph.D.

President and Chief Executive Officer

Dr. Akira Kato joined Shionogi in 1990. In his nearly 30-year tenure with the company, Dr. Kato has led the organization in multiple capacities, including roles as corporate officer and vice president of business development, completing a wide range of transactions with global pharmaceutical and biotechnology companies that included licensing agreements, equity investments and academic collaborations. Prior to his years in business development, Dr. Kato was head of the Pain and Neurology Department for Shionogi’s Discovery Research Laboratories. This leadership role was the culmination of a 20-year scientific career in the central nervous system field where he was responsible for the non-clinical and clinical developments of CNS candidates and significant work in the CNS field through several research collaborations with global pharmaceutical and biotechnology companies. Dr. Kato had been honored as a visiting scientist, Center for Learning and Memory at MIT and has authored or co-authored over 40 peer-reviewed scientific publications. He earned both his master’s degree and Ph.D. in pharmacology from Meijo University in Japan.

  • Joseph Spagnardi
    Joseph Spagnardi joined Shionogi Inc. in June 2013 and is currently Executive Vice President overseeing Legal and Compliance.
    Joseph Spagnardi
  • Nathan McCutcheon
    Nathan McCutcheon joined Shionogi Inc. in December 2019 as Executive Vice President overseeing all commercial aspects of the U.S. business. In this role, Mr. McCutcheon serves as Chief Commercial Officer and is responsible for all sales, marketing, managed care, commercial operations and new product planning. Mr. McCutcheon has an extensive background in all aspects of…
    Nathan McCutcheon